Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5534-5542

  Weinhold, Monika ^a,b   Sommermeyer, Daniel ^b   Uckert, Wolfgang ^b,c   Blankenstein, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; AUTOANTIGEN; EPITOPE; GROWTH INHIBITOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; EXPERIMENTAL TEST; GENE TRANSFER; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR CELL; TUMOR REJECTION; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; C57BL MOUSE; CHICKEN; CLASSIFICATION; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; AUTOIMMUNE DISEASES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHICKENS; EPITOPES, T-LYMPHOCYTE; GROWTH INHIBITORS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL;

EID: 38449100925     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5534     Document Type: Article

References (49)

1. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
2. Chamoto, K., T. Tsuji, H. Funamoto, A. Kosaka, J. Matsuzaki, T. Sato, H. Abe, K. Fujio, K. Yamamoto, T. Kitamura, et al. 2004. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64: 386-390.
3. Morris, E. C., A. Tsallios, G. M. Bendle, S. A. Xue, and H. J. Stauss. 2005. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA. 102: 7934-7939.
4. de Witte, M. A., M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J. Y. Song, M. van der Valk, J. B. Haanen, and T. N. Schumacher. 2006. Targeting self-antigens through allogeneic TCR gene transfer. Blood 108: 870-877.
5. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
6. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317.
7. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65: 319-331.
8. von Herrath, M. G., J. Dockter, and M. B. Oldstone. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1: 231-242.
9. Liu, G. Y., P. J. Fairchild, R. M. Smith, J. R. Prowle, D. Kioussis, and D. C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3: 407-415.
10. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186: 645-653.
11. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13: 829-840.
12. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191: 795-804.
13. Voehringer, D., C. Blaser, A. B. Grawitz, F. V. Chisari, K. Buerki, and H. Pircher. 2000. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J. Immunol. 165: 2415-2422.
14. Gilboa, E. 2001. The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. 2: 789-792.
15. Walker, L. S., and A. K. Abbas. 2002. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2: 11-19.
16. Bachmaier, K., N. Neu, L. M. de la Maza, S. Pal, A. Hessel, and J. M. Penninger. 1999. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283: 1335-1339.
17. Sarukhan, A., C. Garcia, A. Lanoue, and H. von Boehmer. 1998. Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity 8: 563-570.
18. Fossati, G., A. Cooke, R. Q. Papafio, K. Haskins, and B. Stockinger. 1999. Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes. J. Exp. Med. 190: 577-583.
19. Hu, J., W. Kindsvogel, S. Busby, M. C. Bailey, Y. Y. Shi, and P. D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177: 1681-1690.
20. + T cells. J. Exp. Med. 198: 569-580.
21. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
22. Vierboom, M. P., H. W. Nijman, R. Offringa, E. I. van der Voort, T. van Hall, L. van den Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. Melief. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186: 695-704.
23. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
24. Eck, S. C., and L. A. Turka. 2001. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity. Cancer Res. 61: 3077-3083.
25. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166: 2863-2870.
26. Bowne, W. B., R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis, and A. N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190: 1717-1722.
27. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
28. Pircher, H., K. Burki, R. Lang, H. Hengartner, and R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342: 559-561.
29. Gladow, M., W. Uckert, and T. Blankenstein. 2004. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur. J. Immunol. 34: 1882-1891.
30. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.
31. Blanas, E., F. R. Carbone, J. Allison, J. F. Miller, and W. R. Heath. 1996. Induction of autoimmune diabetes by oral administration of autoantigen. Science 274: 1707-1709.
32. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. Carbone, J. F. Miller, and W. R. Heath. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96: 12703-12707.
33. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184: 923-930.
34. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161: 2187-2194.
35. Brown, D. M., T. L. Fisher, C. Wei, J. G. Frelinger, and E. M. Lord. 2001. Tumours can act as adjuvants for humoral immunity. Immunology 102: 486-497.
36. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62: 1120-1124.
37. Morita, S., T. Kojima, and T. Kitamura. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7: 1063-1066.
38. Spiotto, M. T., and H. Schreiber. 2005. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 5: 8.
39. Schambach, A., H. Wodrich, M. Hildinger, J. Bohne, H. G. Krausslich, and C. Baum. 2000. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2: 435-445.
40. Engels, B., H. Cam, T. Schuler, S. Indraccolo, M. Gladow, C. Baum, T. Blankenstein, and W. Uckert. 2003. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14: 1155-1168.
41. Sommermeyer, D., J. Neudorfer, M. Weinhold, M. Leisegang, B. Engels, E. Noessner, M. H. Heemskerk, J. Charo, D. J. Schendel, T. Blankenstein, H. Bernhard, and W. Uckert. 2006. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36: 3052-3059.
42. + T lymphocytes. J. Gene Med. 2: 409-415.
43. + T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177: 3089-3099.
44. Chong, A. S., J. Shen, J. Tao, D. Yin, A. Kuznetsov, M. Hara, and L. H. Philipson. 2006. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311: 1774-1775.
45. Nishio, J., J. L. Gaglia, S. E. Turvey, C. Campbell, C. Benoist, and D. Mathis. 2006. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311: 1775-1778.
46. Suri, A., B. Calderon, T. J. Esparza, K. Frederick, P. Bittner, and E. R. Unanue. 2006. Immunological reversal of autoimmune diabetes without hematopoietic replacement of β cells. Science 311: 1778-1780.
47. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
48. Labrecque, N., L. S. Whitfield, R. Obst, C. Waltzinger, C. Benoist, and D. Mathis. 2001. How much TCR does a T cell need? Immunity 15: 71-82.
49. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.